Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
pH maintenance, Spermicide, Microbicide Lubricant More
A novel selective antimicrobial peptide based on human LL-37 by D-amino acid incorporation. More
The inactivation approach presented in this technology provides for a safe, non-infectious composition for vaccination against the corresponding agent. More
The present invention utilizes the characteristic chemical property of hydrazide groups on one reactant to react with aldehyde groups or cyanate esters on the other reactant with an improved conjugate yield of at least sixty percent. More
A novel mutagenesis system that enables the creation of unmarked and targeted deletions in Burkholderia strains. More
A therapeutic peptide that can prevent intestinal infections by increasing the expression of MUC3 by intestinal epithelial cells. More
A novel cyclized histatin-based peptide DB2-121 that is a potent new antifungal agent active against the clinically important Candida albicans and a number of other organisms. More
We have modified a gene from human RSV which results in the generation of neutralising antibodies and a long-lived and robust protective response against RSV infection More
This technology overcomes the amount of time required to culture and identify pathogens, using standard collection methods, is able to identify over 98% of relevant pathogens, and is a fully automated process More
This is a highly effective vaccine suitable for children and should find utility in endemic regions and as a traveler's vaccine. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Candida
- Cytomegalovirus
- Ebola virus
- Escherichia coli
- Haemophilus influenzae
- Hantavirus
- Helicobacter pylori
- Herpes simplex virus
- Human B19 parvovirus
- Human papilloma virus
- Parainfluenza virus (Type 3)
- Pertussis
- Respiratory syncytial virus RSV
- Rubella
- Salmonella
- Varicella-zoster
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us